SHC-transforming protein 1 (SHC1)

SHC-transforming protein 1 (SHC1) is a ubiquitously expressed adaptor protein that plays a central role in intracellular signal transduction downstream of receptor tyrosine kinases (such as EGFR, insulin receptor, and others)[1][2][3][4]. SHC1 is encoded by the *SHC1* gene on chromosome 1 and exists as three main isoforms—p66Shc, p52Shc, and p46Shc—each with distinct functions and subcellular distributions[1][2][3][4]. Its primary structure features an N-terminal phosphotyrosine-binding (PTB) domain and a C-terminal Src homology 2 (SH2) domain, allowing it to link activated cell surface receptors to major intracellular signaling cascades such as Ras/MAPK and PI3K/AKT pathways[1][2][3][4]. SHC1 is pivotal in regulating cell fate decisions including proliferation, survival, apoptosis, oxidative stress responses, migration, and angiogenesis[1][2][3][4]. Dysregulation and overexpression of SHC1, particularly its p66Shc isoform, is associated with multiple malignancies and implicated as a *prognostic biomarker* and potential therapeutic target in cancer, as well as in aging and neurodegenerative processes[2][4][5]. Direct drug targeting is currently experimental, but its role as a molecular hub in oncogenic and stress-response networks makes SHC1 an area of active translational research[2][4].

Other names

SHCShcASHCASHC-transforming protein 3SHC-transforming protein ASH2 domain protein C1p66p52p46SHC (Src homology 2 domain containing) transforming protein 1Src homology 2 domain-containing-transforming protein C1

Inhibition of SHC1-mediated signal transduction (theoretical/experimental). Disruption of SHC1 interaction with receptor tyrosine kinases or downstream partners (e.g., via peptides or small molecules in research contexts). Modulation of RTK pathways (e.g., EGFR or insulin receptor inhibition indirectly affecting SHC1).